Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: MONOGRAPH

Beta-Alanine

Plain-language summaryIntrigue 60 / 100

Beta-alanine is a non-protein amino acid that serves as the rate-limiting ingredient for muscle carnosine synthesis. Supplementing for four to twelve weeks raises muscle carnosine by 30 to 80 percent, which improves the muscle’s ability to buffer the acid build-up that limits high-intensity exercise. The ergogenic benefit is most reliable for efforts lasting one to four minutes (where lactate buffering is the bottleneck), with meta-analyses showing about 2 to 3 percent improvement. The signature side effect is paresthesia, the harmless but distinct tingling sensation in the face and limbs, attributed to peripheral nerve activation by free beta-alanine. Sustained-release formulations and split dosing reduce the tingle. The relevant pharmacokinetic compartment is muscle carnosine, not plasma. Reference lactate-buffering ergogenic in sport science. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundBasic amino acid

32/100

Mature ergogenic with solid replicated evidence but essentially no research frontier remaining

Cap applied basic-aa cap (max 32)

Look, the science on beta-alanine is basically done. Not in a dismissive way, but in the literal sense: the mechanism is understood, the effect is replicated across multiple labs and meta-analyses, the dose range is characterized, the practical limitations are well-mapped, and the indication space has been fully staked out. For sport science investigators running a specific protocol, thats useful. For researchers looking for an interesting frontier problem, its not.

The carnosine precursor story is real and mechanistically elegant. Beta-alanine loads skeletal muscle carnosine over 4 to 12 weeks by bypassing serum carnosinase, which destroys orally administered carnosine before it reaches tissue. Elevated carnosine then acts as an intracellular pH buffer during high-intensity efforts in the 1 to 4 minute window. Roger Harris’s group established this in the mid-2000s, and the literature since has mostly confirmed and refined it rather than extended it in genuinely new directions. Meta-analyses converge on roughly 2 to 3 percent improvement in that specific exercise window. The effect is real. The question just isn’t very exciting anymore.

What we like: beta-alanine is actually the only practical way to meaningfully load muscle carnosine at scale. Direct carnosine supplementation fails because serum carnosinase cleaves it before it reaches muscle. That gives beta-alanine a legitimate claim as the right tool for carnosine-biology experiments, and the differentiation within that narrow niche is real. Evidence quality is genuinely better than most compounds in this library. Translational signal is solid.

What we don’t like: the ceiling. The question being answered by carnosine loading is narrow and not extending into new biology. No serious lab in 2025 is building a discovery program around beta-alanine unless carnosine is the specific object of study. And even then its a limited probe for a limited question.

The paresthesia profile is probably the most pharmacologically interesting angle the compound has left. Free beta-alanine activates peripheral sensory neurons, likely via MRGPRD receptors, producing the characteristic facial and skin tingling. There’s real neuroscience in that mechanism. But it hasnt generated much productive downstream research, and the effect is mainly a nuisance variable that sustained-release formulations are designed to suppress.

Honestly, if you’re already doing sport physiology research on acid-base dynamics during high-intensity exercise, beta-alanine is already in your toolkit. If you’re asking whether this belongs at the frontier of a discovery-oriented research library, the answer is mostly no. The library should surface what’s next. Beta-alanine is, definitively, what was.

Novelty

22

Mechanism promise

28

In-category differentiation

42

Evidence quality

62

Translational signal

58

Research bench value

42

Rationale Beta-alanine is the canonical carnosine-loading probe with legitimate replicated sport-science evidence, but the mechanism is settled, the indication space is narrow and fully characterized, and novelty is near-floor; the basic-aa structural cap binds at 32 and accurately reflects the research-frontier value for a discovery-oriented library.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Beta-amino acid / carnosine precursor

A non-proteinogenic beta-amino acid; the rate-limiting precursor for muscle carnosine synthesis; an ergogenic supplement that buffers exercise-induced acidosis.

Abstract

Beta-alanine (3-aminopropanoic acid; CAS 107-95-9; molecular formula C3H7NO2; molecular weight 89.09) is a non-proteinogenic beta-amino acid produced endogenously by uracil and dihydrouracil degradation. The compound is the rate-limiting precursor for skeletal muscle carnosine (beta-alanyl-L-histidine) synthesis. Pharmacologically, supplementation over 4 to 12 weeks elevates muscle carnosine by approximately 30 to 80 percent, increasing the muscle’s intracellular pH-buffering capacity during high-intensity exercise. The ergogenic effect is most pronounced for exercise durations of 1 to 4 minutes (where lactate buffering is rate-limiting); meta-analyses show approximately 2 to 3 percent improvement in such efforts. The characteristic side effect is paresthesia (tingling, particularly on face and extremities) attributed to peripheral nerve activation by free beta-alanine; sustained-release formulations and split dosing reduce this. Plasma half-life is approximately 25 minutes; the relevant pharmacokinetic compartment is muscle carnosine, which has a much longer turnover. Used as the canonical lactate-buffering ergogenic in sport science.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-395Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Letrozole

Plain-language summaryIntrigue 62 / 100

Letrozole (Femara) is the most potent of the three approved aromatase inhibitors, suppressing plasma estradiol by 88 to 99 percent at a 2.5 mg daily dose (compared to roughly 80 percent for anastrozole). Approved in 1997 for postmenopausal breast cancer, with slight progression-free survival advantages over anastrozole in head-to-head trials. It is also widely used off-label for ovulation induction (often preferred over clomiphene in polycystic ovary syndrome) and by anabolic steroid users for aggressive estrogen control. The greater potency cuts both ways: more reliable estrogen suppression but more pronounced joint stiffness, fatigue, and bone loss. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

51/100

Potent best-in-class aromatase inhibitor with superb clinical evidence but minimal research novelty

Look, letrozole is about as well-characterized as anything in the aromatase inhibitor space. FDA approved 1997, Novartis’s Femara, multiple phase 3 trials across adjuvant, extended-adjuvant, and metastatic ER-positive breast cancer settings. The BIG 1-98 trial established it against tamoxifen. Head-to-head versus anastrozole in metastatic settings showed modest but real progression-free survival advantage, which lines up cleanly with the pharmacology: letrozole suppresses plasma estradiol by 88-99% at 2.5 mg daily versus anastrozole’s somewhat weaker suppression. Mechanistically, its a textbook competitive, reversible inhibitor of CYP19A1, the triazole scaffold coordinating to the heme iron of the aromatase enzyme. Nothing surprising there.

The reason to have letrozole in a research library isn’t novelty. It’s a reference standard. When you’re running an estrogen-deprivation model in MCF-7 cells or in an ovariectomized rodent and need consistent, deep, reproducible aromatase blockade, letrozole is the tool you reach for. The PPCOS II trial (Legro et al., 2014, NEJM) established its superiority over clomiphene in anovulatory PCOS-related infertility, opening a useful off-label research space. That said, the biology isn’t new. Mechanism is fully mapped, receptor pharmacology well understood, and the clinical outcomes literature is enormous and converged around consistent conclusions.

What we like: the evidence base is about as clean as it gets in outpatient oncology pharmacology. Multiple independent phase 3 trials across different populations, consistent PK (t1/2 roughly 42 hours, hepatic CYP2A6 and CYP3A4 metabolism), and a well-established tolerability profile that makes it a reliable comparator arm. The combination backbone role in CDK4/6 inhibitor trials — palbociclib, ribociclib, abemaciclib — keeps it clinically active in a way older AIs like aminoglutethimide simply aren’t.

What we dont love: from a bench research perspective, letrozole doesn’t give you access to biology you couldn’t otherwise probe. Anastrozole runs the same mechanism slightly less potently. Exemestane approaches it via a steroidal, irreversible route with its own research angle. The novelty axis is essentially at floor for new mechanistic investigation, and the mechanism itself is single-target, well-saturated pharmacology with no real surprises left. The aromatase inhibitor class story has been told.

Honestly, the score here reflects a compound that is excellent at what it does, with outstanding clinical evidence, but offers very little to an investigator hunting frontier biology. It belongs in any serious research library as a validated reference tool and as a probe for estrogen-sensitive systems. Just don’t confuse reliable utility with scientific excitement.

Novelty

18

Mechanism promise

25

In-category differentiation

55

Evidence quality

82

Translational signal

82

Research bench value

68

Rationale Letrozole scores high on evidence quality and translational signal because it carries decades of replicated phase 3 oncology and reproductive endocrinology data, and it earns a solid differentiation mark as the most potent non-steroidal AI. The drag comes from near-zero novelty (FDA-approved 1997, mechanism fully mapped) and an unremarkable single-target mechanism that caps the upper axes hard.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Non-steroidal aromatase inhibitor (third generation)

A potent non-steroidal aromatase inhibitor; superior to anastrozole at suppressing plasma estradiol and used in postmenopausal breast cancer and ovulation induction.

Abstract

Letrozole (4,4′-(1H-1,2,4-triazol-1-ylmethylene)bis(benzonitrile); CAS 112809-51-5; molecular formula C17H11N5; molecular weight 285.31) is a non-steroidal third-generation aromatase inhibitor developed at Novartis and approved by the FDA in 1997 under the trade name Femara. The compound is a more potent aromatase inhibitor than anastrozole, reducing plasma estradiol by approximately 88 to 99 percent at a 2.5 mg daily dose in postmenopausal women. The greater potency translates to slightly superior progression-free survival in head-to-head trials versus anastrozole in metastatic breast cancer, with similar tolerability. Plasma half-life is approximately 42 hours; metabolism is hepatic via CYP2A6 and CYP3A4. Approved indications include adjuvant and metastatic ER-positive postmenopausal breast cancer; off-label use in PCOS-related anovulatory infertility (often more effective than clomiphene per the PPCOS II trial) and as estrogen control in androgen-using populations. Used as the most potent reference aromatase inhibitor.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-277Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Imuracetam

Plain-language summaryIntrigue 25 / 100

Imuracetam is an imidazole-fused piracetam analog with sparse published data. Used as a research compound for racetam structure-activity studies. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

17/100

Soviet-era racetam curiosity with no usable preclinical data and zero clinical footprint

Look, imuracetam sits at the bottom of the racetam survey for a reason. The imidazole fusion to the standard pyrrolidinone scaffold is a real structural innovation on paper, but that’s essentially where the interesting story ends. There is no published dose-finding data in any species, no pharmacokinetic characterization, no replicated preclinical efficacy work, and the Soviet-era reports that exist are thin enough that ‘sparse’ may be generous. This is not a compound with a suppressed or overlooked research track. It just never had one.

The mechanism is assumed to overlap with piracetam, which itself scores in the modest range on this rubric. Indirect cholinergic effects, weak AMPA modulation, membrane fluidity changes. None of that is interesting in 2026 without something new to add, and imuracetam doesn’t add it, at least not in any documented way. The imidazole ring could in theory modulate cholinergic receptor interactions differently than the baseline pyrrolidinone scaffold, but that hypothesis is untested. We’ve got a structural speculation without a research program behind it.

Differentiation from other racetams is essentially zero in practice. Pramiracetam, phenylpiracetam, aniracetam, and coluracetam all carry substantially more preclinical and human-adjacent data. Imuracetam doesn’t compete on any measurable dimension. If you’re building an AMPA-modulator comparison study or doing racetam SAR work, you’d reach for compounds with known characterization data first. Imuracetam as a chemical probe has theoretical appeal, but only if you can source and verify a pure sample, and commercial availability is inconsistent with unverifiable analytical characterization on most vendor batches.

Honestly, the research bench value is mostly as a curiosity within structure-activity relationship surveys of the racetam class. That’s a real but narrow use case, and even there, the absence of any baseline pharmacological data means you’re building a profile from scratch with no reference point. For most research programs, thats a cost that isn’t justified when cleaner analogs exist.

We include it in the library for class completeness and because the imidazole-pyrrolidinone scaffold is, structurally, worth knowing about if you’re doing serious racetam SAR work. But this is a cautionary entry. Obscurity isn’t a research advantage. A compound that’s been available for decades and essentially never studied probably reflects the scientific community’s assessment of its priority. Dont mistake catalog availability for research relevance.

Novelty

25

Mechanism promise

20

In-category differentiation

15

Evidence quality

12

Translational signal

8

Research bench value

20

Rationale Imuracetam scores poorly across nearly every axis: mechanism is inferred from structural analogy to piracetam, evidence is essentially absent by any standard, and no human signal exists in any form. The imidazole substitution is a real structural innovation but remains pharmacologically uncharacterized, and commercial samples carry unverifiable purity profiles that further limit bench utility.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Imidazole-fused pyrrolidinone racetam

An obscure imidazole-substituted racetam from early Soviet pharmacology with sparse published literature.

Abstract

Imuracetam is an imidazole-substituted piracetam analog reported in early Soviet nootropic pharmacology literature. Published data are extremely sparse; the compound never advanced to clinical trials in any jurisdiction and is not approved as a medicine in any market. The structural innovation is fusion of an imidazole ring to the pyrrolidinone scaffold, intended to enhance lipophilicity and modulate the cholinergic profile. Mechanism is incompletely characterized but is thought to overlap with piracetam pharmacology (membrane fluidity, indirect cholinergic, weak AMPA modulation). The compound is occasionally available from research chemical vendors but the chain of custody and analytical characterization on commercial samples is generally unverifiable. Investigators using imuracetam should obtain analytical confirmation of identity and purity before use. There is no human pharmacokinetic data, no formal safety profile, and no dose-finding data in any species. This monograph is provided for completeness of the racetam class survey and as a cautionary entry: not every compound with a “racetam” suffix has substantive published support, and obscurity is itself a research consideration.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-037Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Follistatin 344

Plain-language summaryIntrigue 75 / 100

Follistatin-344 is a 344-amino-acid form of follistatin, a protein that binds and inactivates myostatin (the muscle-growth brake). Used in research for muscle hypertrophy studies. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

34/100

Real myostatin biology but thin peptide-specific evidence and a troubled translational record limit the research case

Here’s the thing about follistatin 344: the underlying biology is genuinely compelling, and thats not nothing. Myostatin, the TGF-beta family member that McPherron and Lee identified in 1997, is one of the most robust negative regulators of skeletal muscle mass we know of. The follistatin/myostatin axis is multi-lab, multi-species validated, and the dramatic phenotype in myostatin-null mice, essentially double-muscled animals, is about as clear a genetic proof-of-concept as you get in muscle biology. The target is real. We’re not arguing otherwise.

What we’re debating is whether FST-344 as a research peptide is the right tool to study it. The 344 isoform is one of two major splice variants encoded by the FST gene; it carries a C-terminal extension with a heparin-binding domain that the 315 form lacks. This affects localization, circulating half-life, and probably how it sequesters activins and BMPs beyond myostatin. That isoform specificity isn’t trivial, and investigators working on tissue-specific follistatin signaling have real reasons to care which form they’re using. But the research peptide market’s FST-344 is not a properly characterized recombinant protein. Serious bench work on this axis typically draws from R&D Systems or Peprotech GMP-grade material with actual QC data behind it, not vendor peptides with unknown aggregation state and uncertain specific activity.

The translational story is complicated. Acceleron’s ACE-031, a soluble ActRIIB-Fc fusion that hits a related biological node by sequestering myostatin, activins, and other TGF-beta ligands, went into Phase 2 in Duchenne muscular dystrophy and was stopped for adverse events including nosebleeds and telangiectasias, with concerning vascular signals. The mechanism isn’t clean in humans: blocking the activin/BMP node broadly touches vascular biology, cardiac function, and bone homeostasis in ways still poorly understood. More recent myostatin-selective antibody programs like apitegromab are trying to thread this needle with better selectivity. Follistatin 344 doesnt offer that selectivity; it binds activin A and B alongside myostatin, which is probably where the vascular signal originates.

The most interesting human-relevant data in the broader field comes from gene therapy work. Jerry Mendell’s group at Nationwide Children’s Hospital has done AAV-delivered follistatin studies in Becker muscular dystrophy and inclusion body myositis, showing real increases in muscle volume on MRI. But thats follistatin as a gene therapy payload, not an injectable peptide, and those translational lessons dont map cleanly onto subcutaneous FST-344 administration. The target remains worth watching as myostatin-selective biologics advance in clinic. This specific form, as sold in the research peptide market without peptide-specific trial data, is not where a serious investigator puts time right now.

Novelty

32

Mechanism promise

48

In-category differentiation

28

Evidence quality

30

Translational signal

28

Research bench value

40

Rationale Myostatin antagonism via follistatin is well-validated multi-lab biology, but FST-344 as a vendor research peptide lacks peptide-specific evidence, the related ACE-031 program was stopped for adverse events, and better-characterized recombinant tools exist for investigators who actually need to work this axis.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Myostatin antagonist / follistatin isoform

An isoform of the endogenous myostatin antagonist follistatin, sold as a research peptide for muscle hypertrophy applications.

Abstract

Follistatin 344 is an isoform of the endogenous protein follistatin (the 344-residue form, encoded as one splice variant of the FST gene). Follistatin binds and antagonizes myostatin (GDF-8), a TGF-beta family member that negatively regulates skeletal muscle mass. Antagonizing myostatin produces increased muscle hypertrophy and reduced muscle atrophy in animal models. Follistatin 344 is sold as a research peptide for muscle development applications. The compound is administered subcutaneously or intramuscularly; oral bioavailability is poor. There is no human clinical trial record for follistatin 344 specifically; the related ACE-031 (a soluble activin receptor type IIB Fc fusion) was developed pharmaceutically and reached Phase 2. Investigational doses range widely with poorly characterized safety; chronic myostatin antagonism may have cardiac and tendon implications that are not adequately studied.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-089Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Alpha-Ketoglutarate (AKG)

Plain-language summaryIntrigue 65 / 100

Alpha-ketoglutarate (AKG) is a TCA cycle intermediate that has shown lifespan extension in mouse studies. Calcium AKG (Ca-AKG) is sold as a longevity supplement, popularized by Rejuvant. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

44/100

Old metabolite with a genuinely interesting epigenetic aging angle, but thin human evidence and COI-clouded pilot data keep it mid-tier

Look, AKG has been sitting in the TCA cycle since the first organisms figured out oxidative metabolism. Calling it novel is a stretch. But there’s a specific modern angle that deserves a serious look: AKG is a required co-substrate for the 2-oxoglutarate-dependent dioxygenase (2-OGDD) superfamily, which includes TET enzymes driving DNA demethylation, JmjC-domain histone demethylases, and prolyl hydroxylases feeding into HIF pathway regulation. When plasma and tissue AKG levels fall with age, which they do, you’re potentially starving a set of enzymes that maintain epigenetic fidelity. That’s a real mechanistic hypothesis, not just “it’s in the Krebs cycle so it must be good.”

The animal data is what put Ca-AKG on the map for longevity researchers. The 2020 work (Shahmirzadi et al., Cell Metabolism) showed Ca-AKG supplementation at 2 percent chow concentration extended healthspan and lifespan in mice, with reduced senescence markers and attenuated inflammaging signals. The C. elegans results are older and show up to 50 percent lifespan extension, though worm data translates poorly. The mouse work is from a real lab with real methodology, but it’s essentially one study from one group at this point.

The human pilot is where things get complicated. Tian et al. 2022 (Aging journal, n=42, open-label) reported roughly 8 years of epigenetic age reduction using Horvath-type methylation clocks after Rejuvant supplementation. What we like: it’s actual human data with a pre-specified methylation endpoint, which is rare in this space. What we dont like: the study is from the Rejuvant commercial team, its open-label with no placebo arm, and epigenetic clocks as primary endpoints remain contested even among clock developers. Replicated, blinded data from independent groups simply doesnt exist yet.

As a bench tool, AKG has real utility for investigators studying 2-OGDD biology or aging-related epigenetic drift. If you’re running a research program on TET enzyme activity, substrate availability experiments are straightforward and informative. The compound is easy to source, stable, and inexpensive. That’s worth something, even if it’s not a sophisticated probe.

We think the 2-OGDD epigenetic aging story is the most interesting thing going on with this compound, and it’s underexplored relative to the NAD+/sirtuin and mTOR spaces that absorb most longevity research attention. But the honest assessment is that the human evidence is one small, conflict-laden pilot, and the mouse mechanism is incompletely worked out. This is a compound worth watching, not one to prioritize. If independent groups replicate the methylation clock findings in a blinded design, the score goes up meaningfully.

Novelty

38

Mechanism promise

58

In-category differentiation

45

Evidence quality

37

Translational signal

35

Research bench value

45

Rationale AKG would normally sit under the foundational-metabolite cap, but the 2-oxoglutarate-dependent dioxygenase story for epigenetic aging qualifies as a novel indication with real (if preliminary) human signal, lifting the cap exemption. Scores land in the low-40s because the mechanism is compelling but the evidence base is thin and largely consortium-sourced.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

TCA cycle intermediate / 2-oxoglutarate

A TCA cycle intermediate sold as calcium alpha-ketoglutarate (Ca-AKG) for longevity applications based on extension of lifespan in mice and worms.

Abstract

Alpha-Ketoglutarate (AKG, 2-oxoglutarate; CAS 328-50-7; molecular formula C5H6O5; molecular weight 146.10) is a tricarboxylic acid cycle intermediate that declines with age in plasma and tissues. The compound is a substrate for the 2-oxoglutarate-dependent dioxygenase family of enzymes (including DNA and histone demethylases, prolyl hydroxylases, and TET enzymes), placing it at a hub of cellular regulation. AKG supplementation extends lifespan in C. elegans (up to 50 percent) and in mice when given as the calcium salt at 2 percent in chow. The mechanism in mice is incompletely characterized but appears to involve reduced cellular senescence, improved metabolic flexibility, and reduced inflammaging markers. Sold as calcium alpha-ketoglutarate (Ca-AKG, Rejuvant) for supplemental use. Doses are typically 500 to 2000 mg per day.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-105Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Idebenone

Plain-language summaryIntrigue 65 / 100

Idebenone is a synthetic CoQ10 analog with better blood-brain barrier penetration. Approved in Europe (Raxone) for Leber hereditary optic neuropathy, a rare mitochondrial eye disease. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

47/100

EU-approved Complex I bypass agent with a validated niche in LHON but failed broader neurodegeneration ambitions

Look, idebenone has something most compounds in this library will never have: a European Medicines Agency approval. Raxone is the recognized pharmacological option for Leber hereditary optic neuropathy, a rare mitochondrial complex I disease that produces acute bilateral vision loss in young adults. That regulatory standing is not performative. The mechanism is tested and clinically anchored in a defined population, and thats worth acknowledging up front before we talk about where it falls short.

The core chemistry was developed by Takeda in the 1980s. The short-chain ubiquinone design, replacing CoQ10’s isoprenoid tail with a hydroxyalkyl chain, substantially improves water solubility and, critically, allows idebenone to function as an electron carrier from cytosolic NADH directly to Complex III, bypassing dysfunctional Complex I entirely. In LHON, where Complex I point mutations block normal electron flow and kill retinal ganglion cells, that bypass is the therapeutic logic. The RHODOS trial established meaningful visual acuity preservation in recently affected eyes, and subsequent long-term observational data has held up reasonably well. Mechanism and clinical outcome are genuinely coherent here.

What we don’t like: the broader bets on idebenone have not paid. The Alzheimer program ran through multiple European consortium trials across the 1990s and 2000s, including a reasonably powered study published in 2003 by Gutzmann and colleagues, and produced results that weren’t compelling enough to generate regulatory interest. The Friedreich ataxia program shows some modest cardiac and neurological endpoint signal but no approval. The DELOS trial in Duchenne muscular dystrophy produced a respiratory rate-of-decline signal that remains inconclusive and hasn’t led anywhere definitive. Each new indication gets a plausible rationale and lands in the modest-to-inconclusive range. Thats a pattern.

Against the modern mitochondrial pharmacology landscape, idebenone also faces more interesting competition. SS-31 targets cardiolipin at the inner mitochondrial membrane via a mechanism idebenone doesn’t touch. MOTS-c drives mitochondrial-nuclear retrograde signaling through AMPK and is genuinely novel as a compound class. MitoQ uses triphenylphosphonium conjugation to concentrate at the inner membrane, a more targeted delivery strategy than the water-soluble ubiquinone scaffold. Idebenone’s design was clever for its era; it’s harder to call it differentiated now.

As a bench tool the compound is legitimately useful. Extensive PK data exists, the dose-response literature in cell lines and animal models is well-characterized, and it’s a clean experimental handle for studying Complex I bypass pharmacology in disease-relevant contexts. If your research program involves mitochondrial electron transport dysfunction, idebenone gives you something real to work with. We’d score it higher if the broader program had materialized or if the mechanism were more contemporary. It didnt, and it isn’t, so here we are at 47.

Novelty

25

Mechanism promise

48

In-category differentiation

50

Evidence quality

60

Translational signal

55

Research bench value

52

Rationale Idebenone earns real credibility from EMA approval for LHON and a mechanistically sound electron-shuttle story, but its 1980s origins, Alzheimer program failures, and the emergence of more mechanistically novel mitochondrial compounds keep novelty and differentiation scores firmly mid-range.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic ubiquinone analog

A short-chain synthetic ubiquinone analog approved in Europe for Leber hereditary optic neuropathy, with reduced lipophilicity and better water solubility than CoQ10.

Abstract

Idebenone (Raxone, Catena, Sovrima; CAS 58186-27-9; molecular formula C19H30O5; molecular weight 338.44) is a synthetic short-chain ubiquinone analog with the 10-carbon isoprenoid tail of CoQ10 replaced by a 10-carbon hydroxyalkyl chain. The structural modification substantially increases water solubility while preserving the redox-cycling quinone chemistry. The compound is approved in Europe (Raxone) for Leber hereditary optic neuropathy, a mitochondrial complex I disease producing acute optic neuropathy. Idebenone bypasses dysfunctional Complex I by directly transferring electrons from cytosolic NADH to Complex III. The compound has also been studied in Alzheimer disease (mixed results, did not advance to FDA approval), Friedreich ataxia (modest effects, no approval), and Duchenne muscular dystrophy. Doses are 900 mg per day in three divided doses for LHON.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-121Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Gonadorelin (GnRH)

Plain-language summaryIntrigue 60 / 100

Gonadorelin is the natural decapeptide GnRH (gonadotropin-releasing hormone) used in research and historical clinical applications for testing pituitary function. Pulsatile administration triggers normal LH and FSH release. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

39/100

FDA-approved diagnostic peptide with settled HPG axis biology and limited novel research interest

Look, the science here was settled before most active investigators were born. GnRH was characterized in the early 1970s; Schally and Guillemin shared a Nobel in 1977 for the work. The pulsatile-versus-continuous duality, the receptor downregulation kinetics, the two-to-four minute plasma half-life — all of it is textbook anterior pituitary endocrinology, and has been for decades. Gonadorelin’s FDA approval for diagnostic pituitary gonadotropin reserve testing is telling: useful enough to approve, not interesting enough to develop further in its native form.

The mechanism is perfectly understood and completely unremarkable as a research target. Pulsatile GnRH receptor stimulation — roughly every 90 minutes, approximating the hypothalamic pulse generator — drives LH and FSH release from the anterior pituitary. Sustained exposure saturates and downregulates the receptor; that’s the entire pharmacological basis for leuprolide, goserelin, and the rest of the long-acting agonist class used in prostate cancer and endometriosis. None of this is contested. It’s elegant biology, but its solved biology. Single-receptor agonism in a maximally-characterized system doesn’t generate mechanism-promise points in 2025.

Where gonadorelin actually shows up in current research is the TRT-adjacent space, specifically pulsatile subcutaneous dosing to maintain HPG axis function and testicular volume in men on exogenous androgens. Thats a real clinical question with a mechanistic rationale. But it’s not a frontier question. HCG handles the same downstream problem at the LH receptor with much longer half-life and a far deeper clinical dataset. The genuinely interesting player on this axis right now is kisspeptin: the upstream GnRH secretagogue with real phase 2 data from the Dhillo group at Imperial and others showing restoration of pulsatile GnRH secretion in hypothalamic amenorrhea and hypogonadotropic hypogonadism. Kisspeptin is where you’d want your grant pointed. Gonadorelin is where you’d point your pipette to run a control condition.

We dont think its worthless as a bench tool. The short plasma half-life is actually a feature for pulse-timing experiments: you can modulate amplitude and frequency without accumulation artifacts that plague longer-acting analogs. For reproductive endocrinology and HPG axis physiology work, it’s a clean, well-characterized probe. That niche has real value. But it’s niche, and it wont appear in the abstract of anything surprising.

The evidence and translational signal scores are the highest here because the compound is FDA-approved and the biology is confirmed across five decades of multi-lab work. But high evidence combined with low novelty is exactly what you’d expect from a 1970s Nobel Prize discovery. If you’re building an HPG axis research program, gonadorelin probably belongs in the cabinet. If you’re deciding where to invest serious investigator hours, look upstream toward kisspeptin or downstream toward the gonadotropin receptor level. Gonadorelin sits in a very well-lit room that everyone has already mapped.

Novelty

18

Mechanism promise

25

In-category differentiation

30

Evidence quality

65

Translational signal

62

Research bench value

45

Rationale Gonadorelin is a Nobel Prize-era compound with completely characterized mechanism and an FDA diagnostic approval; novelty and differentiation scores are low because kisspeptin and long-acting GnRH analogs have claimed the interesting research territory on both sides of it, leaving gonadorelin as a narrow probe tool with real but niche bench utility.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Decapeptide GnRH agonist

Synthetic gonadotropin-releasing hormone, used clinically for diagnostic GnRH stimulation testing and for stimulation of LH/FSH release.

Abstract

Gonadorelin (GnRH, LHRH; CAS 9034-40-6; molecular formula C55H75N17O13; molecular weight 1182.31) is the synthetic decapeptide form of gonadotropin-releasing hormone. The compound is FDA-approved (Factrel) for diagnostic GnRH stimulation testing of pituitary gonadotropin reserve. Pulsatile administration (every 90 minutes) produces physiological LH/FSH release; continuous administration produces receptor downregulation and gonadotropin suppression (the basis for the leuprolide/goserelin class of long-acting analogs used in prostate cancer and endometriosis). Pharmacokinetics: plasma half-life 2 to 4 minutes. Diagnostic dose is 100 micrograms IV. Research-grade applications use the compound for stimulation of endogenous gonadotropin release on testosterone restoration protocols.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-137Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Valerian (Valeriana officinalis)

Plain-language summaryIntrigue 45 / 100

Valerian (Valeriana officinalis) root is a traditional herbal sleep aid. Valerenic acid binds GABA-A receptors and may inhibit GABA reuptake. Clinical effects on sleep are modest in trials. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

26/100

Centuries-old GABAergic herb with modest, inconsistent clinical sleep signal and minimal frontier research value

Look, valerian is one of those compounds that has been on the shelf so long it’s easy to assume theres more to it than there actually is. The root has been used as a sedative for at least two thousand years, the active constituent story is reasonably well worked out (valerenic acid, valepotriates, some GABA reuptake inhibition), and the GABA-A angle sounds interesting until you realize that ‘same pocket as benzodiazepines but with different functional selectivity’ describes a weaker, messier version of pharmacology that much cleaner tools already cover. This is not a compound at the frontier of anything.

The mechanism is real but unremarkable. Valerenic acid modulates GABA-A with a functional selectivity profile that’s distinct from classical benzos, and there is some adenosine A1 agonism layered on top. What we don’t have is a convincing answer to ‘so what?’ The multi-target picture here isn’t the elegant dual-mechanism story you’d tell about, say, tropisetron’s 5-HT3 and alpha-7 angle. It’s a complex botanical mixture with modest, hard-to-standardize pharmacology in one of the most crowded receptor neighborhoods in CNS research.

The evidence base is exactly what you’d expect from three decades of supplement-tier trials. Meta-analyses exist, several of them, and they consistently show effect sizes in the 0.2 to 0.4 range for sleep quality endpoints. That’s statistically detectable and clinically underwhelming. Standardization of extracts across studies is a persistent problem, making cross-trial comparison genuinely difficult. The better-designed trials tend to report smaller effects. There’s no clean phase 2/3 clinical program here with a well-defined patient population and a pre-registered primary endpoint showing something meaningful.

Differentiation is where valerian really struggles. If you’re investigating GABAergic sleep pharmacology, you have zolpidem as a clean reference tool, suvorexant and lemborexant for the orexin angle, and a well-replicated literature on GABA-A subunit selectivity that far exceeds what valerian lets you interrogate. If you’re studying botanical extracts as a class, there are more pharmacologically tractable examples. Valerian sits in a no-mans-land: too mechanistically fuzzy to be a clean probe, too well-known to be novel, and too small in effect size to be a clinical champion.

Honestly, the only real research case for valerian right now is if your program is specifically about botanical GABAergics as a category, comparative herbalism, or traditional medicine validation. thats legitimate work, but it’s not the cutting edge of what most bench investigators are after. We score this low not because it’s junk but because it’s exactly the kind of familiar, low-differentiation compound that a serious research library should deprioritize relative to the actual frontier.

Novelty

20

Mechanism promise

25

In-category differentiation

18

Evidence quality

38

Translational signal

35

Research bench value

28

Rationale Valerian scores low across novelty and differentiation because its mechanism is well-characterized and the effect sizes in humans are small (0.2-0.4 SMD); the OTC herb cap of 35 does not bind because the weighted score falls below it naturally. Bench probe value is narrow and the GABAergic space is saturated with cleaner tools.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Botanical sedative / GABAergic herb

A perennial herb root traditionally used as a mild sedative, characterized by valerenic acid GABA-A modulation.

Abstract

Valeriana officinalis is a perennial herb whose root has been used for centuries as a mild sedative and anxiolytic. Active constituents include valerenic acid and related sesquiterpene acids, plus a complex mixture of valepotriates. Pharmacology includes GABA-A receptor modulation (valerenic acid binds the same receptor pocket as benzodiazepines but with different functional selectivity), modest adenosine A1 receptor agonism, and inhibition of GABA reuptake. Clinical evidence in primary insomnia is mixed; meta-analyses show modest improvements in sleep quality measures with effect sizes in the 0.2 to 0.4 range. Doses are typically 300 to 900 mg of standardized root extract before bedtime.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-153Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Magnesium Taurate

Plain-language summaryIntrigue 48 / 100

Magnesium taurate is magnesium chelated with taurine. Both compounds have cardioprotective and calming effects, and the combination is sometimes preferred for cardiovascular and sleep applications. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundBasic mineral

26/100

A routine magnesium chelate with a modest cardiovascular angle; neither component is novel

Look, magnesium taurate is two familiar supplements sitting in the same capsule, and thats basically the whole story. Magnesium is one of the most well-characterized minerals in human physiology: cofactor for over 300 enzymatic reactions, involved in membrane potential maintenance, vascular smooth muscle tone, and cardiac conduction. Taurine is an osmolyte and calcium-handling modulator with a long track record in cardiovascular research. Combine them as a chelate and you get a form that delivers both simultaneously. What you don’t get is anything genuinely new.

The cardiovascular rationale makes sense on paper. Magnesium deficiency correlates with hypertension and arrhythmia risk, and the evidence for supplementation in deficient populations is real. Taurine has shown modest blood pressure effects in a few small trials, and the cardiac membrane stabilization story is plausible if not fully characterized. Combining the two in a chelate allows for co-delivery, which is the strongest argument for this specific form over plain magnesium or standalone taurine.

Here’s the thing though: the evidence base for the chelate itself is thin. Most of what supports magnesium taurate’s cardiovascular claims is extrapolated from studies on its components individually, not from direct trials on this specific salt. We’re not aware of a landmark study that tests magnesium taurate head-to-head against other magnesium forms on cardiovascular endpoints. The bioavailability is presumably decent, similar to other amino acid chelates, but direct comparison data is sparse. That matters if you’re trying to justify this form over magnesium glycinate, malate, or threonate for a given application.

Compare this to magnesium L-threonate, where the CNS-targeting story comes from actual mechanism work, MIT patent literature, and multiple independent groups showing CSF magnesium elevation that other forms don’t achieve. Magnesium taurate doesn’t have that kind of differentiated story. The combination is logical, the bioavailability is probably fine, but there’s no “only this form does X” claim that holds up under scrutiny. The cardiovascular angle is real but it relies on extrapolating from component studies rather than any head-to-head data on the chelate.

We think this is a perfectly reasonable choice for a research subject who benefits from both compounds, but as a research target it’s not compelling. You’d design a study around it only if you specifically wanted to test combined delivery versus sequential supplementation of the components, and that’s a fairly narrow question with limited publication upside. As a bench probe, it offers nothing unique. As a novel mechanism story, it doesn’t qualify. The score here reflects the reality that stacking two mature, well-characterized compounds in a chelate doesn’t produce research novelty, regardless of how clean the physiological rationale looks on paper.

Novelty

22

Mechanism promise

28

In-category differentiation

30

Evidence quality

25

Translational signal

32

Research bench value

18

Rationale Both magnesium and taurine carry real but thoroughly mature cardiovascular literature; the chelate form adds minimal research value beyond co-delivery convenience, and no direct trials establish this specific salt’s superiority over simpler forms. Calculated overall of 26 sits below the basic-mineral cap of 28, so the cap does not bind.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Magnesium-taurine chelate

A magnesium chelate with taurine emphasized for cardiovascular applications based on combined magnesium and taurine effects.

Abstract

Magnesium taurate is a chelated magnesium salt where magnesium is bound to taurine (2-aminoethanesulfonic acid). The compound is emphasized for cardiovascular applications based on the combined effects of magnesium (membrane stabilization, vascular smooth muscle relaxation) and taurine (osmolyte, calcium handling, cardiac membrane effects). The compound has high bioavailability similar to other amino acid chelates. Doses providing 200 to 400 mg elemental magnesium per day are typical.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-169Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
5-HTP (5-Hydroxytryptophan)

Plain-language summaryIntrigue 55 / 100

5-HTP is the immediate precursor to serotonin, one biosynthetic step closer than tryptophan. Used as a supplement for mood and sleep. Combination with B6 increases conversion efficiency. Should not be combined with serotonergic medications. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

30/100

Well-understood serotonin precursor with modest clinical evidence and low research frontier value

Look, 5-HTP occupies a weird spot in the research landscape. It’s not junk. There are real clinical trials, some with reasonably controlled designs, showing signal in depression and sleep latency. But “not junk” doesn’t make something a compelling bench target in 2026, and thats essentially the problem here.

The mechanism is as simple as it gets. Tryptophan hydroxylase converts tryptophan to 5-HTP; aromatic L-amino acid decarboxylase converts 5-HTP to serotonin. That’s it. The one mechanistically interesting wrinkle, that 5-HTP bypasses large neutral amino acid competition at the BBB and gives more reliable CNS serotonin elevation than tryptophan itself, was characterized decades ago and is now textbook pharmacology. There’s nothing left to figure out here.

The differentiation problem is real. In any serious research program touching serotonergic pharmacology, you have access to direct 5-HT receptor subtype agonists with defined binding profiles, SERT inhibitors with well-characterized kinetics, and tryptophan depletion paradigms as a clean experimental control. 5-HTP sits in the middle of all of these: less clean than receptor-specific tools, less physiologically grounded than tryptophan loading, more variable than SSRIs. It’s not the sharpest tool for any one job.

What we don’t like: the clinical literature is old, scattered, and methodologically weak. The most-cited depression studies are 1970s and 1980s Italian trials with small N and questionable blinding. A Cochrane review called the evidence base insufficient, and that position hasn’t meaningfully changed. The headache and migraine prevention literature is similarly aged and underpowered. Nobody with serious resources is running 5-HTP RCTs right now, and that tells you something about where the field thinks the signal ends.

What we like, to the extent we can: 5-HTP has legitimate utility in serotonin depletion and repletion paradigms at the bench level, and for investigators studying the tryptophan-kynurenine-serotonin axis it’s a useful probe for isolating specific biosynthetic steps. The Griffonia simplicifolia extraction is well-characterized and sourcing is clean. These are minor credits, but they’re real.

Honestly, if your research touches serotonin biology in 2026, the more interesting territory is in 5-HT2A and 5-HT1A subtype pharmacology, the kynurenine pathway upstream, or novel psychoplastogen mechanisms. 5-HTP as a standalone compound answers a question that was already answered. We know it raises CNS serotonin. We know the downstream effects are real but modest and variable. The next question in this space requires different tools.

Novelty

18

Mechanism promise

22

In-category differentiation

25

Evidence quality

45

Translational signal

45

Research bench value

30

Rationale 5-HTP scores low on novelty and mechanism because the tryptophan-to-serotonin precursor chemistry is textbook pharmacology characterized decades ago; moderate evidence and translational scores reflect a real but methodologically weak clinical literature that hasn’t attracted serious new investment since the 1990s.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Serotonin precursor

5-Hydroxytryptophan, the immediate precursor of serotonin, derived from Griffonia simplicifolia seeds and used for mood and sleep applications.

Abstract

5-HTP (5-hydroxytryptophan; CAS 4350-09-8; molecular formula C11H12N2O3; molecular weight 220.23) is the immediate precursor of serotonin in the biosynthesis pathway from tryptophan. The compound is extracted from Griffonia simplicifolia seeds and sold as a dietary supplement. Unlike tryptophan, 5-HTP does not compete with other large neutral amino acids for transport into the CNS, providing more reliable elevation of central serotonin. The compound has been studied for depression, anxiety, sleep, and headache prevention. Use without a peripheral aromatic L-amino acid decarboxylase inhibitor produces peripheral serotonin elevation that may cause GI adverse events. Doses are typically 50 to 300 mg per day. Should not be combined with SSRIs or MAOIs due to serotonin syndrome risk.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-184Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 44 45 46 47 48 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.